Bausch Health Companies Inc
$ 6.02
0.67%
24 Feb - close price
- Market Cap 2,233,117,000 USD
- Current Price $ 6.02
- High / Low $ 6.19 / 5.97
- Stock P/E 14.33
- Book Value -1.50
- EPS 0.42
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.44 %
- 52 Week High 8.69
- 52 Week Low 4.25
About
Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company is headquartered in Laval, Canada.
Analyst Target Price
$7.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 1.1009 | 0.48 | 0.9054 | 0.6069 | 1.16 | 1.13 | 0.027 | 0.6 | 1.15 | 1.02 | 0.82 | 0.52 |
| Estimated EPS | 1.21 | 1.04 | 0.922 | 0.8216 | 1.1267 | 1.02 | 0.88 | 0.72 | 1.02 | 0.92 | 0.78 | 0.72 |
| Surprise | -0.1091 | -0.56 | -0.0166 | -0.2147 | 0.0333 | 0.11 | -0.853 | -0.12 | 0.13 | 0.1 | 0.04 | -0.2 |
| Surprise Percentage | -9.0165% | -53.8462% | -1.8004% | -26.1319% | 2.9555% | 10.7843% | -96.9318% | -16.6667% | 12.7451% | 10.8696% | 5.1282% | -27.7778% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.21 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $1.0 | $0.095 | $0.095 | $0.09 | $0.09 | $0.09 | $0.09 | $0.375 | $0.375 | $0.375 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BHC
2026-02-23 16:39:00
Bausch Health Companies Inc. (BHC) is an oversold pharma stock, with Bank of America raising its price target for Bausch + Lomb (BLCO) due to strong Q4 revenue and positive market outlook. Despite BHC's increased consolidated sales for 2025 and robust performance in its Salix division, concerns about the company's complete separation continue to impact its outlook. The article suggests that while BHC has potential, AI stocks might offer greater returns and less downside risk.
2026-02-23 13:13:41
Bausch Health's aesthetics business, Solta Medical, has launched the Clear + Brilliant® Touch laser in Canada after Health Canada approved the device on May 20, 2025. This launch expands access to advanced non-invasive skin rejuvenation treatments in Canada, building on the successful U.S. launch in 2021. The Clear + Brilliant® Touch laser offers dual-wavelength technology, is suitable for all skin types, and addresses early signs of aging and overall skin appearance.
2026-02-23 13:13:41
Bausch Health's aesthetics division, Solta Medical, has launched its Clear + Brilliant Touch laser in Canada following Health Canada's approval on May 20, 2025. This dual-wavelength fractional laser is designed to address fine lines, wrinkles, skin texture, and pore size, offering customizable, low-downtime skin resurfacing for various skin types. The launch expands Solta's global presence and provides Canadian physicians with advanced technology for non-invasive skin rejuvenation.
2026-02-23 01:35:21
This article provides a comprehensive financial overview of Bausch Health Companies Inc (BHC), detailing its income statement, balance sheet, and cash flow statement for fiscal year 2025 and previous periods. It highlights key financial metrics such as revenue, net income, EBITDA, and EPS, along with an analysis of profitability, growth, liquidity, and leverage. The report also assesses BHC's financial health using metrics like Altman Z-Score, Piotroski F-Score, earnings quality, and interest coverage.
2026-02-21 13:35:07
Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc., announced award-winning actor Bellamy Young as the new spokesperson for their drug Xifaxan. Young will lead a multi-channel campaign to raise awareness about Overt Hepatic Encephalopathy (OHE) recurrence, a complication of cirrhosis, sharing her personal experience with her father's diagnosis. Xifaxan is the only FDA-approved medication to reduce the risk of OHE recurrence in adults.
2026-02-21 12:43:56
Bausch Health significantly improved its CRM experience for its field teams, achieving a 90-95% satisfaction rate. By implementing Veeva CRM MyInsights (now Vault CRM X-Pages), the company consolidated multiple data sets into one "command center," enabling faster decision-making and more productive customer interactions. This streamlined approach allows field teams to access essential information quickly and tailor communication effectively with healthcare professionals.
